| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.1780361206 |
| P698 | PubMed publication ID | 8250987 |
| P50 | author | Peter D Katsikis | Q42434461 |
| P2093 | author name string | J Walker | |
| M Feldmann | |||
| R N Maini | |||
| P Charles | |||
| F M Brennan | |||
| M J Elliott | |||
| J Ghrayeb | |||
| H Bijl | |||
| A Long-Fox | |||
| P2860 | cites work | A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. | Q53438021 |
| P433 | issue | 12 | |
| P921 | main subject | immunology | Q101929 |
| antibody | Q79460 | ||
| rheumatoid arthritis | Q187255 | ||
| rheumatology | Q327657 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1681-1690 | |
| P577 | publication date | 1993-12-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha | |
| P478 | volume | 36 |
| Q71950284 | 2nd International meeting on synovium cell biology, physiology and pathology. Canterbury, United Kingdom, 21-23 September 1994. Proceedings and abstracts |
| Q71576582 | 3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts |
| Q26801912 | A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease |
| Q55001725 | A New Venue of TNF Targeting. |
| Q81184903 | A call for pragmatic treatment trials in rheumatoid arthritis |
| Q28188829 | A clinical and economic review of disease-modifying antirheumatic drugs |
| Q50688343 | A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. |
| Q33923409 | A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis |
| Q93052453 | A fascinating story of the discovery & development of biologicals for use in clinical medicine |
| Q45889035 | A gene therapy approach to treatment of autoimmune disease |
| Q38628540 | A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study |
| Q35945948 | A panel of oxidative stress assays does not provide supplementary diagnostic information in Behcet's disease patients |
| Q40739552 | A partially humanized monoclonal antibody to human IFN-gamma inhibits cytokine effects both in vitro and in vivo |
| Q30629470 | A phage-displayed mimotope inhibits tumour necrosis factor-alpha-induced cytotoxicity more effectively than the free mimotope |
| Q72580333 | A radioreceptor assay for TNF alpha-binding proteins |
| Q33578184 | A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis |
| Q73823415 | A two-step total synthesis of the natural pentacycle trichodimerol, a novel inhibitor of TNF-alpha production |
| Q33782402 | Access to disease modifying treatments for rheumatoid arthritis patients |
| Q106624153 | Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment |
| Q34003178 | Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L. |
| Q36969866 | Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis |
| Q40956233 | Acute-phase proteins in osteoarthritis |
| Q34071292 | Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production |
| Q41133422 | Adhesion molecules in autoimmune disease |
| Q40380711 | Advances in selective immunosuppression. |
| Q74097985 | Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals |
| Q45855775 | Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy |
| Q45868500 | Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery |
| Q37862584 | An evidence-based systematic review on medical therapies for inflammatory bowel disease |
| Q41915136 | An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis |
| Q36271120 | Analysing the effect of novel therapies on cytokine expression in experimental arthritis |
| Q40511583 | Animal models of autoimmune endocrine disease and their uses in developing new methods of intervention |
| Q71662354 | Anti-CD5 therapy decreases severity of established disease in collagen type II-induced arthritis in DBA/1 mice |
| Q33966333 | Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes |
| Q34450313 | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases |
| Q48823077 | Anti-TNF therapy from the bench to the clinic: a paradigm of translational research. |
| Q26997311 | Anti-TNF therapy: past, present and future |
| Q38063585 | Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine |
| Q40963908 | Anti-cytokine therapy in rheumatoid arthritis |
| Q40419253 | Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-alpha 4 antibody in adjuvant arthritis |
| Q48162893 | Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis |
| Q40845933 | Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis |
| Q33782344 | Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis |
| Q40312662 | Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. |
| Q41768035 | Anticytokine approaches in pulmonary fibrosis: bringing factors into focus |
| Q44225152 | Anticytokine therapy--new approach to the treatment of autoimmune and cytokine-disturbance diseases |
| Q35689019 | Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts? |
| Q33641577 | Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety |
| Q34074029 | Apoptosis in rheumatic diseases |
| Q41333546 | Arthritis syndromes associated with human T cell lymphotropic virus type I infection |
| Q41335748 | Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes |
| Q51612919 | Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. |
| Q35557370 | Autoimmune aspects of cytokine and anticytokine therapies |
| Q37891882 | Autoimmunity and inflammation: murine models and translational studies |
| Q34135558 | Averting inflammation by targeting the cytokine environment |
| Q80463745 | B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection |
| Q37253520 | Behavioral Comorbidities in Rheumatoid Arthritis: A Psychoneuroimmunological Perspective. |
| Q40467512 | Beneficial effects of tumour necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis (RA) |
| Q35031727 | Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis |
| Q64899170 | Biofunctional Nanofibrous Substrate for Local TNF-Capturing as a Strategy to Control Inflammation in Arthritic Joints. |
| Q34108783 | Biologic therapies in rheumatoid arthritis |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q35807230 | Biological agents for rheumatoid arthritis: targeting both physical function and structural damage |
| Q38643965 | Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. |
| Q77627751 | Biological insights from clinical trials with anti-TNF therapy |
| Q40436519 | Biological therapies: a novel approach to the treatment of autoimmune disease |
| Q49241439 | CGP 47969A: a novel inhibitor of the synthesis of inflammatory cytokines |
| Q36628197 | Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor. |
| Q34071308 | Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha |
| Q37895016 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years |
| Q36903356 | Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation |
| Q38953729 | Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab |
| Q55174819 | Characterization of Chicken Tumor Necrosis Factor-α, a Long Missed Cytokine in Birds. |
| Q36730236 | Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library |
| Q30839917 | Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis |
| Q33584492 | Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL). |
| Q34229344 | Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis |
| Q35555386 | Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. |
| Q77627740 | Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis? |
| Q58204556 | Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis |
| Q72333296 | Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis |
| Q35010475 | Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities |
| Q71347740 | Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production |
| Q53662356 | Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. |
| Q72194401 | Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins |
| Q41305375 | Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis? |
| Q34427742 | Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible |
| Q35823636 | Current and new antitumor necrosis factor agents in perspective |
| Q34240751 | Current use of biologicals for the treatment of spondyloarthropathies |
| Q35554196 | Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis |
| Q45258734 | Cytokine and nitric oxide production in the acute phase of bacterial cell wall-induced arthritis |
| Q38100529 | Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples |
| Q41209346 | Cytokine inhibitors in autoimmune disease |
| Q73174874 | Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis |
| Q71547893 | Cytokine therapy in rheumatoid arthritis |
| Q28217681 | Cytokine traps: multi-component, high-affinity blockers of cytokine action |
| Q35109131 | Cytokine-based immunointervention in the treatment of autoimmune diseases |
| Q34830551 | Cytokines and anti-cytokine biologicals in autoimmunity: present and future |
| Q41429814 | Cytokines and cell regulation. |
| Q36504371 | Cytokines in idiopathic inflammatory myopathies |
| Q71626854 | Cytokines in rheumatoid arthritis |
| Q48027852 | Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention |
| Q33974537 | Cytokines in rheumatoid arthritis: trials and tribulations |
| Q41625920 | Cytokines: their role in uveal disease |
| Q92398568 | Decoding inflammation, its causes, genomic responses, and emerging countermeasures |
| Q45256819 | Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results |
| Q36364193 | Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators |
| Q36148416 | Design of effective immunotherapy for human autoimmunity |
| Q34672043 | Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis |
| Q74187188 | Development of anti-TNF therapy for rheumatoid arthritis |
| Q34540317 | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies |
| Q37286418 | Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice |
| Q33708846 | Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? |
| Q91934535 | Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases |
| Q40903047 | Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments |
| Q37868002 | Drug-induced lupus erythematosus: incidence, management and prevention |
| Q37208439 | Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. |
| Q40905084 | Early rheumatoid arthritis. Future treatment |
| Q35605942 | Effects of PVA coated nanoparticles on human immune cells |
| Q78344990 | Effects of a PEGylated soluble TNF receptor type 1 (PEG sTNF-RI) on cytokine expression in adjuvant arthritis |
| Q36082965 | Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation |
| Q41133430 | Effects of antirheumatic agents on cytokines |
| Q40975364 | Effects of bucillamine and N-acetyl-L-cysteine on cytokine production and collagen-induced arthritis (CIA). |
| Q38203622 | Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis |
| Q35552265 | Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study |
| Q36172262 | Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent |
| Q35663609 | Electro-acupuncture at acupoint ST36 reduces inflammation and regulates immune activity in Collagen-Induced Arthritic Mice |
| Q41525992 | Emerging treatments for rheumatoid arthritis |
| Q24793680 | Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky |
| Q72508194 | Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids |
| Q40305814 | Enhancement of anti-inflammatory tendency by SB203580, p38alpha specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A. |
| Q40980471 | Enhancement of the surface expression of tumor necrosis factor alpha (TNFalpha) but not the p55 TNFalpha receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors |
| Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
| Q50980583 | Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. |
| Q57306277 | Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis |
| Q37316594 | Evidence that cytokines play a role in rheumatoid arthritis |
| Q43873302 | Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis |
| Q40976385 | Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis |
| Q39706642 | Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? |
| Q36133726 | Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis |
| Q45765388 | Expression of TNF alpha in arthritis caused by caprine arthritis encephalitis virus |
| Q38571447 | From IFN to TNF: a journey into realms of lore |
| Q35559305 | From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease |
| Q37374541 | Functional CD40 ligand is expressed by T cells in rheumatoid arthritis |
| Q34071336 | Future prospects for anti-cytokine treatment |
| Q45885240 | Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis |
| Q41702950 | Gene therapy for rheumatoid arthritis. Theoretical considerations. |
| Q42860789 | Genetic traits in common diseases |
| Q35882362 | Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. |
| Q40684555 | Gold sodium thiomalate (GSTM) inhibits lipopolysaccharide stimulated tumor necrosis factor-alpha through ceramide pathway |
| Q37786627 | Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis |
| Q28207155 | HLA class II and TNF genes in African Americans from the Southeastern United States: regional differences in allele frequencies |
| Q36252940 | Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States |
| Q46767224 | Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis |
| Q34731292 | How does infliximab work in rheumatoid arthritis? |
| Q74449418 | Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha) |
| Q42744057 | IL-10: Another therapeutic target in idiopathic pulmonary fibrosis? |
| Q39137044 | Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity. |
| Q90345211 | Immunogenicity of TNF-Inhibitors |
| Q33655250 | Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? |
| Q40506587 | Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus |
| Q41722148 | Immunological treatment of autoimmune diseases. |
| Q42643514 | Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study |
| Q42942352 | Immunoregulatory role of interleukin 10 in rheumatoid arthritis |
| Q41719098 | Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A |
| Q73647747 | In vitro effect of gold sodium thiomalate and methotrexate on tumor necrosis factor production in normal healthy individuals and patients with rheumatoid arthritis |
| Q35798600 | In vivo expression of monokine and inducible nitric oxide synthase in experimentally induced pulmonary granulomatous inflammation. Evidence for sequential production of interleukin-1, inducible nitric oxide synthase, and tumor necrosis factor |
| Q35550051 | Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors |
| Q74497673 | Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope |
| Q35084908 | Infection complications associated with the use of biologic agents |
| Q43539087 | Inflammation in dry eye associated with rheumatoid arthritis: cytokine and in vivo confocal microscopy study |
| Q33885648 | Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group |
| Q44477953 | Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease |
| Q52856626 | Infliximab for rheumatoid arthritis. |
| Q36099482 | Infliximab for the treatment of early rheumatoid arthritis |
| Q34758388 | Infliximab for the treatment of rheumatoid arthritis |
| Q35554918 | Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study |
| Q41860347 | Infliximab in ulcerative colitis. |
| Q35127601 | Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. |
| Q34963107 | Infliximab treatment for rheumatic disease: clinical and radiological efficacy |
| Q35553775 | Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit |
| Q35201036 | Infliximab treatment of rheumatoid arthritis and Crohn's disease |
| Q35555743 | Infliximab treatment reduces complement activation in patients with rheumatoid arthritis |
| Q46598130 | Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients |
| Q33959133 | Infliximab: a review of its use in the management of rheumatoid arthritis |
| Q36573901 | InforMatrix: treatment of rheumatoid arthritis using biologicals |
| Q34339207 | Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. |
| Q59400563 | Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina |
| Q35630027 | Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases |
| Q36172826 | Interleukin 6 plays a key role in the development of antigen-induced arthritis |
| Q74552397 | Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis |
| Q40892440 | Is there a future for extracorporeal photochemotherapy in the treatment of the rheumatological diseases? |
| Q51072387 | Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System. |
| Q34626968 | Juvenile rheumatoid arthritis: therapeutic perspectives |
| Q28206018 | Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases |
| Q34775626 | Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis |
| Q39830747 | Local expression of tumor necrosis factor alpha in an experimental model of acute osteomyelitis in rats |
| Q44470590 | Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion |
| Q73117771 | Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy |
| Q38008340 | Macrophages in synovial inflammation |
| Q39467334 | Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities |
| Q41167186 | Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? |
| Q37316591 | Many cytokines are very useful therapeutic targets in disease |
| Q71803587 | Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo |
| Q43640818 | Mechanism of action of disease modifying anti-rheumatic agent, gold sodium thiomalate (GSTM). |
| Q33747158 | Medical options for treating Crohn's disease in adults: focus on antitumor necrosis factor-alpha chimeric monoclonal antibody |
| Q57079507 | Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression |
| Q61940702 | Modulation of cytokine production by human mononuclear cells following impairment of Na,K-ATPase activity |
| Q30480303 | Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells |
| Q35026014 | Monoclonal antibodies in immune and inflammatory diseases |
| Q40693747 | Monoclonal antibodies in the treatment of rheumatoid arthritis |
| Q34236658 | Monoclonal antibody therapy |
| Q38116065 | Monoclonal antibody treatments for rheumatoid arthritis |
| Q40433213 | Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease |
| Q45856471 | NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts |
| Q73232529 | NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy |
| Q46157260 | Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis |
| Q57780174 | Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis |
| Q33668883 | New therapeutic targets for rheumatoid arthritis |
| Q33758853 | New treatments for rheumatoid arthritis. Available and upcoming slow-acting antirheumatic drugs |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q34108901 | Non-HIV retroviral associations with rheumatic disease |
| Q38561971 | Noncoding RNAs and chronic inflammation: Micro-managing the fire within. |
| Q99560991 | Noncompetitive allosteric antagonism of death receptor 5 by a synthetic affibody ligand |
| Q73895528 | Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-alpha suppressing and IL-10 augmenting activity |
| Q73313502 | Oncostatin M induces leukocyte infiltration and cartilage proteoglycan degradation in vivo in goat joints |
| Q83133754 | Optic neuritis after infliximab therapy |
| Q35116177 | Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases |
| Q73218778 | PAF modulates eicosanoids and TNF release in immune-complex arthritis in rats |
| Q33782360 | PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases |
| Q91774708 | Parallel comparison of fibroblast-like synoviocytes from the surgically removed hyperplastic synovial tissues of rheumatoid arthritis and osteoarthritis patients |
| Q40681350 | Pediatric rheumatic diseases. |
| Q38357886 | Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs |
| Q92055384 | Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice |
| Q72995693 | Polymorphisms in the 5'-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis |
| Q79603683 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone |
| Q24675216 | Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 |
| Q74339945 | Prevention of collagen-induced arthritis in DBA/1 mice by oral administration of AZ-9, a bacterial polysaccharide from Klebsiella oxytoca |
| Q40861531 | Pro- and anti-inflammatory cytokines in rheumatoid arthritis |
| Q59059630 | Processing of tumour necrosis factor-α precursor by metalloproteinases |
| Q54619618 | Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. |
| Q43524051 | Progress in development of herpes simplex virus gene vectors for treatment of rheumatoid arthritis |
| Q40968027 | Prospects of immunotherapy for rheumatoid arthritis |
| Q40848847 | Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy? |
| Q39947228 | Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis? |
| Q35547725 | Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging |
| Q28239197 | Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis |
| Q44966729 | Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. |
| Q24805049 | Regulation and localization of endogenous human tristetraprolin |
| Q52689527 | Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease. |
| Q73521731 | Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint |
| Q71678987 | Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis |
| Q92798584 | Remicade® (infliximab): 20 years of contributions to science and medicine |
| Q42694138 | Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis |
| Q36751123 | Repeated, but not acute, stress suppresses inflammatory plasma extravasation |
| Q42113714 | Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes. |
| Q36755055 | Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. |
| Q26822029 | Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease |
| Q38753468 | Review of pulmonary adverse effects of infliximab therapy in Crohn's disease |
| Q57349151 | Rheumatoid arthritis |
| Q71046923 | Rheumatoid arthritis |
| Q34572250 | Rheumatoid arthritis and tumor necrosis factor alpha |
| Q36011107 | Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy |
| Q34706975 | Rheumatoid arthritis: developing pharmacological therapies |
| Q72126768 | Rheumatology |
| Q35541858 | Role of Monocytes in Atherogenesis |
| Q41209333 | Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. |
| Q40648766 | Role of hsp70 in cytokine production |
| Q77627732 | Role of pro-inflammatory cytokines in rheumatoid arthritis |
| Q40498828 | Role of the biologics in autoimmunity |
| Q58831756 | Role of tumor necrosis factor-α and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis |
| Q38823319 | SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use? |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q35937819 | Serious infections associated with anticytokine therapies in the rheumatic diseases |
| Q24804764 | Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept |
| Q72002723 | Serum cytokines in patients with rheumatoid arthritis. Correlation of interferon gamma and tumor necrosis factor alpha with the characteristics of peripheral blood mononuclear cells |
| Q34255262 | Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation |
| Q61628146 | Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF |
| Q77118243 | Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis |
| Q24647121 | Sulfasalazine-induced immune thrombocytopenia |
| Q45864343 | Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy |
| Q35132863 | Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis |
| Q41837521 | Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis |
| Q71627291 | Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat |
| Q37584747 | Systems approaches to human autoimmune diseases |
| Q36687908 | Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis |
| Q53655184 | TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. |
| Q38303870 | TNF antagonists opened the way to personalized medicine in rheumatoid arthritis |
| Q34240744 | TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept |
| Q37412511 | TNF-alpha and its inhibitors in cancer |
| Q36361083 | TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications? |
| Q36349618 | Tacrolimus in rheumatoid arthritis |
| Q37229283 | Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis |
| Q35144028 | Targeting cytokines in autoimmunity: new approaches, new promise |
| Q34436456 | Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases |
| Q38179171 | Temporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis |
| Q74404685 | Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells |
| Q40442396 | Th1 and Th2 cells in autoimmunity |
| Q54406138 | Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A production |
| Q35336802 | The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug |
| Q97526637 | The Balance of TNF Mediated Pathways Regulates Inflammatory Cell Death Signaling in Healthy and Diseased Tissues |
| Q54380161 | The association between TNFα gene polymorphisms and susceptibility to rheumatoid arthritis in an ethnic Kashmiri population: relationship with disease activity and severity markers. |
| Q53431391 | The contingent ranking method--a feasible and valid method when eliciting preferences for health care? |
| Q41265044 | The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target |
| Q79366300 | The effect of infliximab on chemokines in patients with rheumatoid arthritis |
| Q37385249 | The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis |
| Q40859444 | The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis |
| Q37197292 | The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery |
| Q41558341 | The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines |
| Q33784067 | The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy |
| Q33566525 | The prospect for cytokine based therapeutic strategies in rheumatoid arthritis |
| Q33527432 | The protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis |
| Q33782321 | The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? |
| Q43755430 | The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis |
| Q41170697 | The role of cytokines in rheumatoid arthritis. The Croonian Lecture 1995. |
| Q73323617 | The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts |
| Q37784863 | The roles of TNF in brain dysfunction and disease |
| Q35164732 | The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis |
| Q34108762 | The treatment of rheumatoid arthritis: a review of recent clinical trials |
| Q96229604 | The trimer to monomer transition of Tumor Necrosis Factor-Alpha is a dynamic process that is significantly altered by therapeutic antibodies |
| Q71889641 | The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice |
| Q35688168 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview |
| Q36916918 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an update |
| Q40581267 | The value of C-reactive protein measurement in rheumatoid arthritis |
| Q40651825 | Therapeutic advances in immunosuppression |
| Q77995733 | Therapeutic antibodies elicited by immunization against TNF-alpha |
| Q43741023 | Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection |
| Q37129557 | Therapeutic efficacy of intra-articular adrenomedullin injection in antigen-induced arthritis in rabbits. |
| Q56344227 | Therapeutic implications of how TNF links APOE, P-tau, α-synuclein, β-amyloid, and insulin resistance in neurodegenerative diseases |
| Q40458523 | Therapeutic modulation of cytokines |
| Q40518542 | Therapy for multiple sclerosis. |
| Q24806367 | Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches |
| Q58175004 | Time course of circulating acute phase proteins and cytokines in septic patients |
| Q26783490 | Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications |
| Q58259640 | Transgenic Models for Arthritis: Useful Clues to Be Gained? |
| Q73502940 | Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q37607063 | Treatment of rheumatoid arthritis: state of the art 2009. |
| Q33946522 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab |
| Q61863535 | Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis |
| Q35554567 | Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies |
| Q55248422 | Trivalent soluble TNF Receptor, a potent TNF-α antagonist for the treatment collagen-induced arthritis. |
| Q80821536 | Tumor necrosis factor alpha -308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q34000190 | Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. |
| Q74628468 | Tumor necrosis factor alpha regulation of the FAS-mediated apoptosis-signaling pathway in synovial cells |
| Q73691790 | Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system |
| Q48325336 | Tumor necrosis factor gene polymorphisms in adult patients with autoimmune hemolytic anemia. |
| Q34276023 | Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis |
| Q90211848 | Tumor necrosis factor-driven cell death in donor organ as a barrier to immunological tolerance |
| Q37535116 | Tumor necrosis factor-α potentiates long-term potentiation in the rat dentate gyrus after acute hypoxia |
| Q57079509 | Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis |
| Q34406958 | Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity |
| Q38102726 | Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective. |
| Q33782315 | Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis |
| Q38200925 | Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective |
| Q34181975 | Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis |
| Q35351045 | Tumour necrosis factor-alpha enhances intraepithelial lymphocyte proliferation and migration |
| Q24812796 | Tumour necrosis factor-alpha stimulates dehydroepiandrosterone metabolism in human fibroblast-like synoviocytes: a role for nuclear factor-kappaB and activator protein-1 in the regulation of expression of cytochrome p450 enzyme 7b |
| Q36094915 | Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. |
| Q55396890 | Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. |
| Q38988559 | Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics |
| Q33753656 | Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis |
| Q33588350 | Update in internal medicine |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q35553451 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). |
| Q34962946 | Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). |
| Q35579352 | Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. |
| Q35579517 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
| Q34560553 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) |
| Q73566782 | Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis |
| Q44599587 | Value of anti-TNF-alpha molecules in inflammatory and infectious diseases |
| Q73820269 | Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease |
| Q58691977 | What Have We Learned about the Pathogenesis of Rheumatoid Arthritis from TNF-Targeted Therapy? |
| Q30826279 | What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort |
| Q36437505 | What makes a good anti-inflammatory drug target? |
| Q50567309 | Willingness to pay in arthritis: a Danish contribution. |
| Q73182174 | [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis] |
| Q84600286 | [Rapid application of infliximab. Efficacy and complications] |
| Q73370072 | [Rheumatoid arthritis: new molecular and cellular aspects] |
| Q74042917 | [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors] |
| Q73164408 | [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis] |
Search more.